Drug intelligence / Profile preview

allogenic fecal microbiota transplant

Development stage: Unknown
Lead developer: Taylored Biotherapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

Allogenic fecal microbiota transplant (FMT) is an investigational biologic therapy being evaluated for the treatment of bipolar depression. The intervention, led by researcher Dr. Valerie Taylor, involves the transfer of gut microbiota from healthy, screened donors to patients with bipolar disorder. The primary mechanism of action is the modulation of the patient's gut microbiome, which is believed to influence mental health through the gut-brain axis. In a pilot randomized controlled trial, the therapy is administered via colonoscopy and compared against an autologous FMT (using the patient's own stool) as a placebo. This experimental approach is being investigated as an adjunctive treatment for patients with bipolar depression who have not responded adequately to standard therapies. The research is primarily associated with the University of Toronto, Women's College Hospital, and the University of Calgary.

Other names: Fecal microbiota transplantationFMT

Beyond the preview

Go deeper on allogenic fecal microbiota transplant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allogenic fecal microbiota transplant.

Explore the full profile